Search
Menu
Home
HTB
2021
February
February 2021
Contents
Editorial
HTB: no. 2 – plus HIV and COVID-19 (24 February 2021)
In memory
In memory: Elias Phiri – community HIV and TB advocate
In memory: Dr Joseph Sonnabend – pioneer HIV activist and researcher
Timothy Ray Brown: a virtual memorial
Conference reports
R4P virtual conference (2021)
VRC01 antibody only prevents minority of HIV infections: AMP study results
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
Promising data for multipurpose technologies to prevent HIV and pregnancy
12th International Workshop on HIV paediatrics
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1
Drug resistance
UK study for people with triple-class drug resistance
Treatment advocacy
Community murals in Soweto on dolutegravir-based ART: an i-Base collaboration
COVID-19: HIV and COVID-19 coinfection
HIV positive people in the UK now elligible for COVID vaccinations – and to become available at HIV clinics
COVID-19: vaccine research
What are the main COVID-19 variants? How can they affect vaccine responses?
Novavax: >90% efficacy in UK but 60% in South Africa, hints of lower effect in HIV positive participants
Russian Sputnik vaccine reports 91% efficacy at 21 days after the first dose
Janssen vaccine reports efficacy after single injection: FDA decision imminent
Oxford/AZ vaccine might still prevent severe COVID-19 from B.1.351 variant: supports continued used in South Africa
Unprecedented rapid speed of COVID vaccine development
WHO online vaccine tracker
COVID-19 vaccine pricing: a BBC guide
COVID-19: treatment access
High rates of undocumented COVID-19 mortality in Zambia without testing challenges the idea that Africa has been spared
COVID-19: investigational drugs
Tocilizimab effectively reduces COVID-19 related deaths and hospitalisation time: additive benefit with dexamethasone
Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study
US FDA specifies high antibody titre for convalescent plasma and to only use in early COVID-19
No benefit from convalescent plasma in UK RECOVERY study: limited results restrict implications for COVID-19
COVID-19: pathogenesis
UK variant B.1.1.7 linked to higher risk of death and hospitalisation from COVID-19
PDFs
HTB no 2 – plus HIV and COVID-19 (24 February 2021)
HTB RSS
Early access
IAS-USA update in drug resistance mutations (2025)
29 May 2025
Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV
27 May 2025
US update guidelines for statin use in people living with HIV
26 May 2025
HIV activists in the US call for action in JID and Zachie Achmat brings South African perspective in the Lancet
26 May 2025
All early access reports
Current issues
May 2025
April 2025
March 2025
Back issues
Special report
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate